Literature DB >> 21900892

From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020.

J C Kovacic1, V Fuster.   

Abstract

Cardiovascular disease (CVD) has become the most common cause of mortality worldwide. Obesity, insufficient physical exercise, diabetes, and advancing age are major risk factors for developing cardiovascular disease that are currently increasing in prevalence. Nevertheless, significant progress has recently been made in the treatment of complex cardiovascular and coronary artery disease (CAD), with pharmacological management set to assume an increasingly important role. Other timely factors, such as the development of the polypill and high-level medical and political interest in advancing cardiovascular health, are driving forces that may help to make inroads into the global cardiovascular disease burden. In this article, we critically review the key challenges that we face in the coming decade as we strive to transition and apply our growing knowledge of complex CAD to promoting global cardiovascular health.

Entities:  

Mesh:

Year:  2011        PMID: 21900892     DOI: 10.1038/clpt.2011.173

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Acute coronary syndromes: pathology, diagnosis, genetics, prevention, and treatment.

Authors:  Valentin Fuster; Jason C Kovacic
Journal:  Circ Res       Date:  2014-05-13       Impact factor: 17.367

Review 2.  "Second-generation" stem cells for cardiac repair.

Authors:  Alberto Núñez García; Ricardo Sanz-Ruiz; María Eugenia Fernández Santos; Francisco Fernández-Avilés
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

3.  Smoking gun theory: angiographically normal or mild coronary plaque as a cause of myocardial infarction.

Authors:  Jason C Kovacic; Valentin Fuster
Journal:  Circulation       Date:  2012-11-20       Impact factor: 29.690

4.  Vascular calcification, diabetes, and cardiovascular disease: connecting the dots.

Authors:  Jason C Kovacic; Valentin Fuster
Journal:  JACC Cardiovasc Imaging       Date:  2012-04

5.  Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization.

Authors:  Jason C Kovacic; Atul M Limaye; Samantha Sartori; Paul Lee; Roshan Patel; Sweta Chandela; Biana Trost; Swathi Roy; Rafael Harari; Birju Narechania; Rucha Karajgikar; Michael C Kim; Prakash Krishnan; Pedro Moreno; Usman Baber; Roxana Mehran; George Dangas; Annapoorna S Kini; Samin K Sharma
Journal:  Catheter Cardiovasc Interv       Date:  2013-07-01       Impact factor: 2.692

Review 6.  Inflammation, heart disease, and depression.

Authors:  Angelos Halaris
Journal:  Curr Psychiatry Rep       Date:  2013-10       Impact factor: 5.285

Review 7.  Cardiovascular defense challenges at the basic, clinical, and population levels.

Authors:  Jason C Kovacic; Jose M Castellano; Valentin Fuster
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 6.499

8.  Water-soluble acacetin prodrug confers significant cardioprotection against ischemia/reperfusion injury.

Authors:  Hui Liu; Lei Yang; Hui-Jun Wu; Kui-Hao Chen; Feng Lin; Gang Li; Hai-Ying Sun; Guo-Sheng Xiao; Yan Wang; Gui-Rong Li
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

Review 9.  Sulforaphane Protects against Cardiovascular Disease via Nrf2 Activation.

Authors:  Yang Bai; Xiaolu Wang; Song Zhao; Chunye Ma; Jiuwei Cui; Yang Zheng
Journal:  Oxid Med Cell Longev       Date:  2015-10-25       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.